北美人胰岛素药物市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

北美人胰岛素市场按药物(基础或长效胰岛素、丸剂或速效胰岛素、传统人胰岛素、组合胰岛素和生物仿制胰岛素)和地理划分。

市场快照

North American Human Insulin Drugs Market Overview
Study Period: 2016-2027
Base Year: 2021
CAGR: 4.41 %
North American Human Insulin Drugs Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

北美人胰岛素药物市场预计在 2020-2025 年的预测期内复合年增长率为 4.41%,预计到 2025 年市场价值将达到 120 亿美元。北美主导着全球胰岛素治疗市场,由于久坐不动的生活方式和该地区新药的推出,该地区糖尿病的高发病率。由于肥胖率高和该地区对糖尿病护理意识的提高等因素,预计美国在预测期内将大幅增长。

报告范围

北美人胰岛素市场按药物(基础或长效胰岛素、推注或速效胰岛素、传统人胰岛素、联合胰岛素和生物仿制药胰岛素)和地理区域划分。

By Drug
Insulin (Value and Volume 2012-2025)
Basal or Long-acting Insulin
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast-acting Insulin
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
FIASP (Insulin aspart)
Admelog (Insulin lispro)
Traditional Human Insulin
Novolin/Actrapid/Insulatard
Humulin
Insuman
Combination Insulin
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Soliqua/Suliqua (Insulin glargine/Lixisenatide)
Biosimilar Insulin
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Geography
North America
United States (Value and Volume 2012-2025)
Basal or Long-acting Insulin
Bolus or Fast-acting Insulin
Traditional Human Insulin
Combination Insulin
Biosimilar Insulin
Canada (Value and Volume 2012-2025)
Basal or Long-acting Insulin
Bolus or Fast-acting Insulin
Traditional Human Insulin
Combination Insulin
Biosimilar Insulin
Rest of North America (Value and Volume 2012-2025)
Basal or Long-acting Insulin
Bolus or Fast-acting Insulin
Traditional Human Insulin
Combination Insulin
Biosimilar Insulin

Report scope can be customized per your requirements. Click here.

主要市场趋势

美国主导市场

在北美国家中,美国占北美人胰岛素药物市场总量的 94% 左右。这主要是由于该国糖尿病患病率高。美国记录了全球最高的医疗保健支出,并且采用先进疗法的比例也更高。2017年胰岛素市场规模为106亿美元,预计预测期内(2020-2025年)市场复合年增长率为4.29%。此外,美国是长效胰岛素来得时在整个北美地区销量最高的地区。大多数糖尿病药物制造公司认为该国是提高全球整体销售的关键市场。来得时是世界上使用量最大的基础胰岛素,

North American Human Insulin Drugs Market Key Trends

Humalog 在 2019 年拥有最高的市场份额。

Humalog 在 2019 年占据了最大的市场份额。然而,由于市场上存在类似的甘精胰岛素,如 FIASP 和 Admelog,预计该产品在预测期内将减少。Admelog 被证明可以降低 A1C,类似于 Humalog。Admelog 可在 Admelog SoloStar 笔或小瓶中使用,并可用于泵中。2019年3月,礼来在美国推出其赖脯胰岛素注射液(Humalog)的授权仿制药。新仿制药 Humalog 的标价比市场上现有的 Humalog 标价低 50%。

North American Human Insulin Drugs Market Growth by Region

竞争格局

北美人胰岛素市场高度分散,三大制造商占有很大的市场份额。在美国,除了诺和诺德、赛诺菲、礼来,再无其他玩家。而在其余国家/地区,制造商仅限于其他当地或特定地区的制造商。近期参与者之间发生的并购有助于这些公司加强其市场占有率。礼来(Eli Lilly)和勃林格殷格翰(Boehringer Ingelheim)共同开发和商业化 Basaglar(甘精胰岛素)。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug

      1. 5.1.1 Insulin (Value and Volume 2012-2025)

        1. 5.1.1.1 Basal or Long-acting Insulin

          1. 5.1.1.1.1 Lantus (Insulin Glargine)

          2. 5.1.1.1.2 Levemir (Insulin Detemir)

          3. 5.1.1.1.3 Toujeo (Insulin Glargine)

          4. 5.1.1.1.4 Tresiba (Insulin Degludec)

          5. 5.1.1.1.5 Basaglar (Insulin Glargine)

        2. 5.1.1.2 Bolus or Fast-acting Insulin

          1. 5.1.1.2.1 NovoRapid/Novolog (Insulin Aspart)

          2. 5.1.1.2.2 Humalog (Insulin Lispro)

          3. 5.1.1.2.3 Apidra (Insulin Glulisine)

          4. 5.1.1.2.4 FIASP (Insulin aspart)

          5. 5.1.1.2.5 Admelog (Insulin lispro)

        3. 5.1.1.3 Traditional Human Insulin

          1. 5.1.1.3.1 Novolin/Actrapid/Insulatard

          2. 5.1.1.3.2 Humulin

          3. 5.1.1.3.3 Insuman

        4. 5.1.1.4 Combination Insulin

          1. 5.1.1.4.1 NovoMix (Biphasic Insulin Aspart)

          2. 5.1.1.4.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

          3. 5.1.1.4.3 Xultophy (Insulin Degludec and Liraglutide)

          4. 5.1.1.4.4 Soliqua/Suliqua (Insulin glargine/Lixisenatide)

        5. 5.1.1.5 Biosimilar Insulin

          1. 5.1.1.5.1 Insulin Glargine Biosimilars

          2. 5.1.1.5.2 Human Insulin Biosimilars

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States (Value and Volume 2012-2025)

          1. 5.2.1.1.1 Basal or Long-acting Insulin

          2. 5.2.1.1.2 Bolus or Fast-acting Insulin

          3. 5.2.1.1.3 Traditional Human Insulin

          4. 5.2.1.1.4 Combination Insulin

          5. 5.2.1.1.5 Biosimilar Insulin

        2. 5.2.1.2 Canada (Value and Volume 2012-2025)

          1. 5.2.1.2.1 Basal or Long-acting Insulin

          2. 5.2.1.2.2 Bolus or Fast-acting Insulin

          3. 5.2.1.2.3 Traditional Human Insulin

          4. 5.2.1.2.4 Combination Insulin

          5. 5.2.1.2.5 Biosimilar Insulin

        3. 5.2.1.3 Rest of North America (Value and Volume 2012-2025)

          1. 5.2.1.3.1 Basal or Long-acting Insulin

          2. 5.2.1.3.2 Bolus or Fast-acting Insulin

          3. 5.2.1.3.3 Traditional Human Insulin

          4. 5.2.1.3.4 Combination Insulin

          5. 5.2.1.3.5 Biosimilar Insulin

  6. 6. MARKET INDICATORS

    1. 6.1 Type 1 Diabetes Population (2012-2025)

    2. 6.2 Type 2 Diabetes Population (2012-2025)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 COMPANY PROFILES

      1. 7.1.1 Novo Nordisk A/S

        1. 7.1.1.1 Overview

        2. 7.1.1.2 Products and Strategies

        3. 7.1.1.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.1.4 Ratio Analysis (5 Years)

        5. 7.1.1.5 Strength and Stability Analysis (5 Years)

        6. 7.1.1.6 Recent Developments

      2. 7.1.2 Sanofi S.A.

        1. 7.1.2.1 Overview

        2. 7.1.2.2 Products and Strategies

        3. 7.1.2.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.2.4 Ratio Analysis (5 Years)

        5. 7.1.2.5 Strength and Stability Analysis (5 Years)

        6. 7.1.2.6 Recent Developments

      3. 7.1.3 Eli Lilly and Company

        1. 7.1.3.1 Overview

        2. 7.1.3.2 Products and Strategies

        3. 7.1.3.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.3.4 Ratio Analysis (5 Years)

        5. 7.1.3.5 Strength and Stability Analysis (5 Years)

        6. 7.1.3.6 Recent Developments

      4. 7.1.4 Biocon Limited

        1. 7.1.4.1 Overview

        2. 7.1.4.2 Products and Strategies

        3. 7.1.4.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.4.4 Ratio Analysis (5 Years)

        5. 7.1.4.5 Strength and Stability Analysis (5 Years)

        6. 7.1.4.6 Recent Developments

      5. 7.1.5 Pfizer Inc.

        1. 7.1.5.1 Overview

        2. 7.1.5.2 Products and Strategies

        3. 7.1.5.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.5.4 Ratio Analysis (5 Years)

        5. 7.1.5.5 Strength and Stability Analysis (5 Years)

        6. 7.1.5.6 Recent Developments

      6. 7.1.6 Wockhardt

        1. 7.1.6.1 Overview

        2. 7.1.6.2 Products and Strategies

        3. 7.1.6.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.6.4 Ratio Analysis (5 Years)

        5. 7.1.6.5 Strength and Stability Analysis (5 Years)

        6. 7.1.6.6 Recent Developments

      7. 7.1.7 Julphar

        1. 7.1.7.1 Overview

        2. 7.1.7.2 Products and Strategies

        3. 7.1.7.3 Recent Developments

      8. 7.1.8 Exir

        1. 7.1.8.1 Overview

        2. 7.1.8.2 Products and Strategies

        3. 7.1.8.3 Recent Developments

      9. 7.1.9 Sedico

        1. 7.1.9.1 Overview

        2. 7.1.9.2 Products and Strategies

        3. 7.1.9.3 Recent Developments

    2. 7.2 COMPANY SHARE ANALYSIS

      1. 7.2.1 Novo Nordisk AS

      2. 7.2.2 Sanofi S.A.

      3. 7.2.3 Eli Lilly and Company

      4. 7.2.4 Other Companies

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

Market size and volume of individual drugs provided for every country

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The North America Human Insulin Drugs Market market is studied from 2016 - 2027.

The North America Human Insulin Drugs Market is growing at a CAGR of 4.41% over the next 5 years.

Sanofi S.A., Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc, Biocon Limited are the major companies operating in North America Human Insulin Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!